MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Crinetics Pharmaceuticals Inc

Deschisă

SectorSănătate

32.1 1.1

Rezumat

Modificarea prețului

24h

Curent

Minim

31.35

Maxim

33.41

Indicatori cheie

By Trading Economics

Venit

-3.8M

-81M

EPS

-0.88

Marjă de profit

-18,560.15

Angajați

437

EBITDA

-6.9M

-94M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+134.2% upside

Dividende

By Dow Jones

Următoarele câștiguri

8 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-405M

2.8B

Deschiderea anterioară

31

Închiderea anterioară

32.1

Scor tehnic

By Trading Central

Încredere

Very Strong Bullish Evidence

Crinetics Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 apr. 2025, 23:54 UTC

Acțiuni populare

Stocks to Watch: Alphabet, Intel, AppFolio

24 apr. 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 apr. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 apr. 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 apr. 2025, 23:37 UTC

Top știri

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 apr. 2025, 23:36 UTC

Top știri

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 apr. 2025, 23:13 UTC

Top știri
Câștiguri

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 apr. 2025, 23:09 UTC

Top știri

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 apr. 2025, 23:02 UTC

Achiziții, Fuziuni, Preluări

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 apr. 2025, 23:02 UTC

Achiziții, Fuziuni, Preluări

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 apr. 2025, 22:51 UTC

Top știri
Achiziții, Fuziuni, Preluări

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 apr. 2025, 22:48 UTC

Top știri

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 apr. 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 apr. 2025, 22:38 UTC

Market Talk
Câștiguri

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 apr. 2025, 22:24 UTC

Câștiguri

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 apr. 2025, 22:24 UTC

Câștiguri

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 apr. 2025, 22:24 UTC

Market Talk
Câștiguri

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 apr. 2025, 22:23 UTC

Câștiguri

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 apr. 2025, 22:11 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

24 apr. 2025, 22:11 UTC

Market Talk
Câștiguri

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 apr. 2025, 22:09 UTC

Top știri
Câștiguri

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 apr. 2025, 22:00 UTC

Market Talk
Câștiguri

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 apr. 2025, 21:39 UTC

Top știri

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 apr. 2025, 21:24 UTC

Top știri
Câștiguri

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 apr. 2025, 21:24 UTC

Top știri
Câștiguri

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 apr. 2025, 21:23 UTC

Top știri
Câștiguri

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 apr. 2025, 21:04 UTC

Câștiguri

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 apr. 2025, 21:03 UTC

Câștiguri

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 apr. 2025, 21:03 UTC

Câștiguri

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 apr. 2025, 21:02 UTC

Câștiguri

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Comparație

Modificare preț

Crinetics Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

134.2% sus

Prognoză pe 12 luni

Medie 78.2 USD  134.2%

Maxim 100 USD

Minim 53 USD

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCrinetics Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

12 ratings

11

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

31.27 / N/ASuport & Rezistență

Termen scurt

Very Strong Bullish Evidence

Termen mediu

Neutral Evidence

Termen lung

Neutral Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.